Search the MBS

Lung ventilation study using Galligas and lung perfusion study using gallium-68 macro aggregated albumin (⁶⁸Ga-MAA), with PET, if the service is performed because the service to which item 61348 applies cannot be performed due to unavailability of technetium-99m (R)

Bulk bill incentive

Fee: $443.35 Benefit: 75% = $332.55 85% = $376.85

(See para IN.4.4 of explanatory notes to this Category)

• Previous - Item 61329
• Next - Item 61336

Cerebral study, with PET, if the service is performed because the service to which item 61402 applies cannot be performed due to unavailability of technetium-99m (R)

Bulk bill incentive

Fee: $605.05 Benefit: 75% = $453.80 85% = $514.30

(See para IN.4.4 of explanatory notes to this Category)

• Previous - Item 61333
• Next - Item 61340

Bone study – whole body with PET, with delayed imaging when undertaken, if the service is performed because the services to which item 61421 or 61425 apply cannot be performed due to unavailability of technetium-99m (R)

Bulk bill incentive

Fee: $600.70 Benefit: 75% = $450.55 85% = $510.60

(See para IN.4.4 of explanatory notes to this Category)

• Previous - Item 61340
• Next - Item 61345

Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.(R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61505
• Next - Item 61524

Whole body FDG PET study, performed for the staging of locally advanced (Stage III) breast cancer, for a patient who is considered suitable for active therapy (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61523
• Next - Item 61525

Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61524
• Next - Item 61527

Whole body study using PET, if the service is performed because the services to which items 61429, 61430, 61442, 61450 or 61453 apply cannot be performed due to the unavailability of gallium-67 (R)

Bulk bill incentive

Fee: $752.35 Benefit: 75% = $564.30 85% = $653.65

(See para IN.4.4 of explanatory notes to this Category)

• Previous - Item 61525
• Next - Item 61529

Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61527
• Next - Item 61538

FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy. (R)

Bulk bill incentive

Fee: $901.00 Benefit: 75% = $675.75 85% = $802.30

• Previous - Item 61529
• Next - Item 61541

Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61538
• Next - Item 61553